Medtronic’s diabetes business MiniMed looks for $784m in US IPO

Diabetes specializer MiniMed has launched an archetypal nationalist offering (IPO) to bolster its superior reserve amid its ongoing divided from genitor company, Medtronic.

Through this projected offering, MiniMed volition relinquish 28 cardinal shares of its communal stock, which are acceptable to beryllium listed connected the Nasdaq Global Select Market nether the ticker “MMED”. Shares are expected to beryllium priced astatine betwixt $25 and $28.

Alongside its archetypal offering, MiniMed volition connection underwriters a 30-day enactment to bargain up to 4.2 cardinal further shares astatine the IPO terms minus underwriting discounts and commissions.

Once the IPO is completed, Medtronic volition ain betwixt 88.70% and 90.03% of MiniMed’s shares, depending connected however overmuch further banal the underwriters acquisition during the hold period.

Medtronic plans to usage astir $350m of the nett proceeds from this IPO for “general firm purposes”, portion the remainder volition spell towards repaying MiniMed’s owed intercompany indebtedness to Medtronic. These dues were accrued aft Medtronic transferred assets to MiniMed pursuing its strategical divided successful May 2025, which volition spot the second go an autarkic company.

Medtronic accrued these dues aft it transferred assets to MiniMed pursuing its strategical divided successful May 2025, which volition spot the second go an autarkic company.

MiniMed generated $2.7bn successful yearly gross during fiscal twelvemonth 2025, with a nett nonaccomplishment of $198m, according to an S-1 filing submitted to the US Securities and Exchange Commission (SEC).

As MiniMed separates from its genitor company, the caller medtech subordinate is looking astatine ways to go the go-to diabetes instrumentality supplier connected the market.

While it volition look beardown contention from companies similar Abbott Laboratories and Dexcom, MiniMed could clasp an vantage implicit its rivals owed to its implicit insulin absorption ecosystem, including inulin pumps, continuous glucose monitoring (CGM) and dosing algorithms.

MiniMed has been making steps to bolster its portfolio successful caller months, with the company’s insulin transportation system, MiniMed 780G precocious achieving a trio of milestones successful benignant 2 diabetes – including US Food and Drug Administration (FDA) clearance and Medicare entree to the strategy successful February 2026.

This follows 780G’s caller European CE statement enlargement to children aged 2 years and above, large radical and those with benignant 2 insulin-requiring diabetes.

According to the S-1 filing, MiniMed besides has immoderate third-generation automated insulin transportation (AID) systems successful development. This includes the MiniMed Flex insulin pump, which the institution has already submitted to the FDA for approval. MiniMed expects to taxable the insulin pump for CE people support successful Q1 2026. The institution is besides looking to record for the FDA support of its Fit spot pump with extended deterioration successful the “fall of calendar twelvemonth 2026”.